Psychedelics

The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Champignon Brands Inc. for violations of §§10 and 20 of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.Investors who purchased the Company's securities between March 27, 2020 and February 17, 2021, inclusive are encouraged ...

The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Champignon Brands Inc. ("Champignon" or "the Company") (OTC Pink: SHRMF) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.

Investors who purchased the Company's securities between March 27, 2020 and February 17, 2021, inclusive (the ''Class Period''), are encouraged to contact the firm before June 9, 2021.

If you are a shareholder who suffered a loss, click here to participate.

We also encourage you to contact Brian Schall of the Schall Law Firm, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm's website at www.schallfirm.com, or by email at brian@schallfirm.com.

The class, in this case, has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member.

According to the Complaint, the Company made false and misleading statements to the market. Champignon failed to maintain sufficient internal controls over financials. The Company's issued financial statements were false and could not be relied upon, and required restatement. The Company engaged in acquisitions with undisclosed third parties. As a result, the British Columbia Securities Commission would suspend the Company from trading. Based on these facts, the Company's public statements were false and materially misleading throughout the class period. When the market learned the truth about Champignon, investors suffered damages.

Join the case to recover your losses.

The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.

CONTACT:

The Schall Law Firm
Brian Schall, Esq.,
www.schallfirm.com
Office: 310-301-3335
info@schallfirm.com

SOURCE:

The Schall Law Firm

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/86853

News Provided by Newsfile via QuoteMedia

Optimi Health

Optimi Health Completes Expansion Of On-Site Analytical Laboratory

Optimi Health Corp . (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN) ("Optimi" or the "Company"), is pleased to announce that it has completed a planned expansion of the on-site analytical laboratory at its Princeton, British Columbia facility.

The on-site lab is purpose built inside one of Optimi's EU-GMP capable 10,000 square foot, state-of-the-art indoor growing facilities dedicated to the cultivation of safe, high-quality psychedelic and functional mushrooms. Optimi Chief Science Officer, Justin Kirkland, will oversee the Company's analytical operations.

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less

COMPASS Pathways plc announces first quarter 2022 financial results and business highlights

-

Highlights:
  • End of phase II meeting held with FDA
  • Award of Innovation Passport as part of the UK MHRA Innovative Licensing and Access Pathway ILAP
  • Finalising phase III in TRD program design to be ready for second half of 2022
  • Pioneering collaboration with King's College London and South London and Maudsley NHS Foundation Trust, to create The Centre for Mental Health Research and Innovation in the UK
  • Cash position at 31 March 2022 of $243.7 million
  • Conference call today at 8:00am ET (1:00pm UK)

COMPASS Pathways plc (Nasdaq: CMPS) ("COMPASS"), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, today reported its financial results for the first quarter 2022 and gave an update on recent progress across its business.

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less
NeonMind Biosciences

NeonMind Biosciences


Keep reading...Show less
Optimi Health

Optimi Health Applauds Health Canada's Position on Drug Quality and Goods and Manufacturing Practices for Psilocybin

Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN) ("Optimi" or the "Company") CEO, Bill Ciprick, issued a statement today in response to Health Canada's May 6 Notice to Stakeholders "regarding the proposed use of psilocybin mushrooms in clinical trials, or as a drug accessed through the Special Access Program (SAP)."

Ciprick says the Notice published by Health Canada's Office of Legislative and Regulatory Affairs Controlled Substances Directorate was welcomed by Optimi, specifically around the "importance of drug quality and Good Manufacturing Practices (GMP)."

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less

COMPASS Pathways to fund study of COMP360 psilocybin in autistic adults

London, UK 9 May 2022

COMPASS Pathways plc (Nasdaq: CMPS) ("COMPASS"), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, today announced it will be funding an investigator-initiated study that will use COMP360 psilocybin to explore how psilocybin affects specific brain pathways in autistic adults. This will be the first ever mechanistic study of psilocybin in autistic adults.

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less
Awakn Life Sciences to Participate in Upcoming May 2022 Conferences

Awakn Life Sciences to Participate in Upcoming May 2022 Conferences

Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB: AWKNF) (FSE: 954) ('Awakn'), a biotechnology company, researching, developing, and delivering combined therapeutics to treat addiction, announced today that Awakn's management team is scheduled to present at the following upcoming May 2022 conferences.

PSYCH Symposium: London 2022

News Provided by Newsfile via QuoteMedia

Keep reading...Show less

Latest Press Releases

Related News

×